Next Article in Journal
A Role for Circular Non-Coding RNAs in the Pathogenesis of Sporadic Parathyroid Adenomas and the Impact of Gender-Specific Epigenetic Regulation
Next Article in Special Issue
The Role of Lipids in Parkinson’s Disease
Previous Article in Journal
The Fate of Fusions
Previous Article in Special Issue
Epigenetic Study in Parkinson’s Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain
Open AccessArticle

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

1
Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
2
Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
3
Medical Technology Innovation Center, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan
*
Authors to whom correspondence should be addressed.
Cells 2019, 8(1), 14; https://doi.org/10.3390/cells8010014
Received: 29 November 2018 / Revised: 20 December 2018 / Accepted: 25 December 2018 / Published: 29 December 2018
(This article belongs to the Special Issue The Molecular and Cellular Basis for Parkinson's Disease)
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD. View Full-Text
Keywords: Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine
Show Figures

Figure 1

MDPI and ACS Style

Ueno, S.-I.; Saiki, S.; Fujimaki, M.; Takeshige-Amano, H.; Hatano, T.; Oyama, G.; Ishikawa, K.-I.; Yamaguchi, A.; Nojiri, S.; Akamatsu, W.; Hattori, N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease. Cells 2019, 8, 14.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop